The Biotrend USA Group Letter

The Biotrend USA Group wishes you a very happy new year 2025!

Dear readers, 

After a year 2024 rich in projects, we are delighted to present to you Biotrend USA' initiatives for the year 2025, reflecting our constant commitment in the fields of research and diagnostics. 

We are particularly proud to announce the  imminent publication of the results of a clinical study sponsored by the Limoges University Hospital on Oncogramme® (CE/IVD) , our functional diagnostic test for metastatic colorectal cancer. These results will allow us to accelerate the deployment of Oncogramme®, both in France and on a European and international scale. 

On the other hand,  the acceleration of patient inclusions in our other clinical study, ONCOG1 , promoted by our subsidiary Oncomedics and conducted in collaboration with the Saint-Joseph Hospital in Marseille, illustrates our determination to offer this technology to all oncologists. This test is a valuable tool to support them in choosing the right treatments for their patients with metastatic colorectal cancer. 

The year 2024 was also marked by significant investments , including our participation in the capital increase of Genexpath, a Rouen-based company offering CE/IVD marked kits for the diagnosis of sarcomas (SarcomaFusion) and lymphomas (LymphoSign), as well as in X'Prochem and Sirius NeoSight, a Lyon-based company specializing in the study of circulating tumor cells. These strategic collaborations underline our commitment to diversifying our offerings in order to better meet the constantly evolving needs of oncology diagnostics and production methods. 

Finally, Biotrend USA affirms its role as a committed player attentive to market developments, by actively seeking  opportunities for commercial partnerships and strategic investments  in the fields of oncology, bioproduction and preclinical research. 

Our ambition is to maintain a continuous dynamic of innovation and to play a key role in the progress of medical sciences across the 15 European countries where we are established, while strengthening our teams each year. 

Wishing you the best for 2025.

Tushendan Rasiah

CEO Biotrend USA Group

News from our PHRCI clinical study

News from the ONCOG1 study (Innovation Package) 

This randomized clinical study of Oncogramme® Metastatic Colorectal Cancer (mCRC) is being conducted by the Limoges University Hospital, and more specifically the department of Professor Mathonnet, in collaboration with Oncomedics and with the partnership of 13 French hospital centers. 

Follow-up data from the 256 patients  in this clinical study are currently being analyzed, with final results expected in 2025.  

The treatments analyzed within the framework of the Oncogramme® CRCm are the following: Folfirinox, Folfox, Folfiri and 5FU + Folinic Acid.

This randomized clinical study of Oncogramme® is being conducted by the Saint-Joseph Hospital in Marseille, and more specifically the department of Dr. Perrier, in collaboration with Oncomedics, for patients with metastatic colorectal cancer (mCRC). ONCOG1 follows Oncomedics' obtaining of the Innovation Package in 2019, supported by the HAS and the Ministry of Health.

The ONCOG1 study aims to enroll  450 patients , for whom inclusions are currently ongoing. The treatments analyzed in this clinical study are not only chemotherapies or combinations of chemotherapies (Folfirinox, Folfox, Folfiri and 5FU + Folinic Acid,) but also targeted therapies prescribed to treat metastatic colorectal cancer. The primary completion date of this study is scheduled for the end of 2025, with an estimated date of final completion in December 2026. 

A look back at the inauguration of the new Oncomedics premises

Biotrend USA selected for the 4th edition of the ETIncelles 2024 program!

It was last Friday, October 18th and it was for us one of the most significant moments of the year! The inaugural day of the new Oncomedics premises was an opportunity for the subsidiary of the Biotrend USA Group to showcase its expertise in medical innovation and in particular Oncogramme®.

On the program for this event: a visit to the laboratories, meetings with all the healthtech players and entrepreneurs in the Limousin region, and two conferences on the financing issues of the sector and innovative companies in the region.

A big thank you to the more than  70 participants  of this day as well as to the speakers of the round tables: Olivier Chabanon, CEO of France Biotech; Magali Granger, President of Strat'Up Visor; Bruno Génin, entrepreneur and investor in the health sector; Emile Roger Lombertie, Mayor of Limoges; Hugo de Gentile, impact entrepreneur; Laure Sandoval, President of Sanodev; and Mehdi Hammouche, Deputy CEO of Limoges Métropole.

Biotrend USA Group is proud to announce its selection for the 4th edition of the ETIncelles 2024 program, a prestigious initiative supported by the Directorate General for Enterprises. This recognition highlights our commitment to growth, innovation and our ambition to become a mid-sized company (ETI). 

Being selected among these 46 companies  is a recognition of our hard work and our strategic vision. This opportunity will allow us to strengthen our development, both in France and internationally, and to continue to innovate to meet the growing needs of scientific and medical research.

An unforgettable weekend in Marrakech for the Biotrend USA Group

In November 2024, members of the Biotrend USA group met in Marrakech for an exceptional weekend. This event brought together nearly  100 employees  from our various European offices, offering a unique moment of sharing, discovery and conviviality.

This weekend allowed our teams to meet in a warm and exotic setting. The moments of exchange strengthened the bonds between our employees, creating an atmosphere of mutual assistance and collaboration that reflects our values ​​on a daily basis.

This highlight would not have been possible without the warm welcome from our Moroccan office.

On the program:

• Immersive activities to discover local culture;
• Moments of relaxation to share between different members of the group.

This weekend in Marrakech embodied the strength of our group: a community of committed talents, driven by a spirit of innovation and collaboration.